نتائج البحث

1

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

المؤلفون: Lei Huo, Gaiane M. Rauch, Alyson Clayborn, Tanbin Rahman, Pamela McCarthy, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Stacy L. Moulder, Clinton Yam, W. Fraser Symmans, Jason B White, James Stec, Sausan Abouharb, Bora Lim, Jennifer K. Litton, Senthil Damodaran, Meghan Sri Karuturi, Ryan Sun

المصدر: Investigational New Drugs. 39:509-515

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6b9d56eaf08effcaff310abab6d9d7Test
https://doi.org/10.1007/s10637-020-00995-2Test

2

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

المصدر: Investigational new drugs, vol 39, iss 1
Invest New Drugs

مصطلحات موضوعية: 0301 basic medicine, Oncology, Organoplatinum Compounds, Metastatic pancreatic adenocarcinoma, Leucovorin, Phases of clinical research, Kaplan-Meier Estimate, Polyethylene Glycols, 0302 clinical medicine, FOLFOX, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), 6.2 Cellular and gene therapies, Cancer, education.field_of_study, Pharmacology and Pharmaceutical Sciences, Middle Aged, Progression-Free Survival, Interleukin-10, Tolerability, Pancreatic Ductal, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, IL-10, Fluorouracil, Pegilodecakin, Drug, Carcinoma, Pancreatic Ductal, medicine.drug, Adult, medicine.medical_specialty, Clinical Trials and Supportive Activities, Population, Phase 1, Article, Dose-Response Relationship, Pancreatic Cancer, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Pegylated IL-10, Adverse effect, education, Response Evaluation Criteria in Solid Tumors, Neoplasm Staging, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, Carcinoma, Evaluation of treatments and therapeutic interventions, digestive system diseases, Oxaliplatin, Pancreatic Neoplasms, Regimen, 030104 developmental biology, Tumor progression, Digestive Diseases, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69d0ddd9f3551a8ca0a4d0daab7d846Test
https://doi.org/10.1007/s10637-020-01000-6Test

3

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

المصدر: Invest New Drugs

مصطلحات موضوعية: Mesothelioma, Male, 0301 basic medicine, Oncogene Proteins, Fusion, Ligands, Gastroenterology, Hyperphosphatemia, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, FGF, Pharmacology (medical), Aged, 80 and over, Middle Aged, Treatment Outcome, Pemetrexed, Oncology, 030220 oncology & carcinogenesis, Female, Fibroblast Growth Factor 2, medicine.drug, Adult, medicine.medical_specialty, Combination therapy, Recombinant Fusion Proteins, Antineoplastic Agents, Phase 1, Article, 03 medical and health sciences, Pharmacokinetics, Internal medicine, medicine, Humans, Receptor, Fibroblast Growth Factor, Type 1, Adverse effect, Aged, Pharmacology, Cisplatin, business.industry, Mesothelioma, Malignant, Cancer, medicine.disease, 030104 developmental biology, Immunoglobulin G, Ligand trap, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f79fa27ba3514b5c0a71da97b74f5a9Test
https://doi.org/10.1007/s10637-019-00783-7Test

4

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

المؤلفون: Xuejing Wang, Katherine M Bell-McGuinn, Jimmy Hwang, Johanna C. Bendell, Hans Christian Reinhardt, Daphne L. Farrington, Celine Pitou, Helge Bischoff, Robert M. Campbell, Thomas Zander, Scott M. Hynes, Philip W. Iversen, Michael Thomas

المصدر: Investigational New Drugs. 38:1145-1155

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Pyridines, Population, Antineoplastic Agents, Models, Biological, p38 Mitogen-Activated Protein Kinases, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Lung cancer, Adverse effect, education, Protein Kinase Inhibitors, Aged, Pharmacology, education.field_of_study, business.industry, Imidazoles, Cancer, Common Terminology Criteria for Adverse Events, Middle Aged, medicine.disease, Treatment Outcome, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, Pyrazines, 030220 oncology & carcinogenesis, Checkpoint Kinase 1, Pyrazoles, Ralimetinib, Female, business, Febrile neutropenia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e75a04ddc23ef75c870beb94be16d9dTest
https://doi.org/10.1007/s10637-019-00873-6Test

5

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials

المؤلفون: Sanjay Goel, Audrey E. Kam, Ioannis Mantzaris, Santiago Aparo, Andreas Kaubisch, M. H. Ghalib, Gopichand Pendurti, Jennifer W. Chuy, Umang Shah, Imran Chaudhary, Lakshmi Rajdev

المصدر: Invest New Drugs

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Maximum Tolerated Dose, Colorectal cancer, Disease, Article, Survival outcome, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Tissue Distribution, Pharmacology (medical), Progression-free survival, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Pharmacology, Models, Statistical, Framingham Risk Score, business.industry, Patient Selection, Phase 1 trials, Phase i trials, Middle Aged, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Prognostic model, Female, Colorectal Neoplasms, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e7980ad2672d11c6f466b0df5b1adf3Test
https://doi.org/10.1007/s10637-018-0675-9Test

6

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy

المؤلفون: Takaaki Tokito, Takashi Kojima, Hidenobu Ishii, Norikazu Matsuo, Kazuhiko Yamada, Tomoaki Hoshino, Koichi Azuma

المصدر: Investigational new drugs. 39(4)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Combination therapy, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Disease, Gastroenterology, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Immune system, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Adverse effect, Lung cancer, Immune Checkpoint Inhibitors, Pneumonitis, Aged, Retrospective Studies, Pharmacology, Aged, 80 and over, Chemotherapy, business.industry, Incidence (epidemiology), Incidence, Middle Aged, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33e9c0562b5d14a59198e2debd0714Test
https://pubmed.ncbi.nlm.nih.gov/33483882Test

7

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

المؤلفون: Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo

المصدر: Investigational New Drugs. 36:683-695

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Ruxolitinib, Placebo, Disease-Free Survival, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Clinical endpoint, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, business.industry, Hazard ratio, Janus Kinase 1, Janus Kinase 2, Middle Aged, medicine.disease, Chemotherapy regimen, Pancreatic Neoplasms, Clinical trial, Pyrimidines, 030104 developmental biology, 030220 oncology & carcinogenesis, Disease Progression, Pyrazoles, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4efb9dd95fab56ab09c97a08030248fTest
https://doi.org/10.1007/s10637-018-0580-2Test

8

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients

المؤلفون: Sarah Guégan, François Goldwasser, Nathalie Franck, Nora Kramkimel, Anne Jouinot, Valentine Heidelberger, Nicolas Dupin, Selim Aractingi, Jérôme Alexandre, Jennifer Arrondeau, Audrey Mansuet-Lupo, Diane Damotte, Marie-Françoise Avril

المصدر: Investigational New Drugs. 35:842-847

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Immune system, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm Invasiveness, Pharmacology (medical), 030212 general & internal medicine, Progression-free survival, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Pharmacology, Response rate (survey), Performance status, Brain Neoplasms, business.industry, Antibodies, Monoclonal, Middle Aged, Prognosis, medicine.disease, Survival Rate, Nivolumab, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Cohort, Immunology, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a072285a15e850dd8f9b54bd56a2d0Test
https://doi.org/10.1007/s10637-017-0476-6Test

9

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

المؤلفون: Monica M. Mita, Filip Janku, Ronald B. Natale, Aung Naing, Wei Guo, Razelle Kurzrock, Siqing Fu, Sarina Anne Piha-Paul, Alain C. Mita, C. Zhao

المصدر: Investigational New Drugs. 35:616-626

مصطلحات موضوعية: Adult, Male, Niacinamide, 0301 basic medicine, MAPK/ERK pathway, Maximum Tolerated Dose, MAP Kinase Kinase Kinase 1, MAP Kinase Kinase Kinase 2, Pharmacology, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Stable Disease, Refractory, Pharmacokinetics, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pimasertib, Pharmacology (medical), Adverse effect, Protein Kinase Inhibitors, Stomatitis, Aged, Aged, 80 and over, Sirolimus, business.industry, TOR Serine-Threonine Kinases, Middle Aged, medicine.disease, Temsirolimus, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6f1cae671876d1b4d3af544b954972Test
https://doi.org/10.1007/s10637-017-0442-3Test

10

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

المؤلفون: Donald A. Richards, Wu Chou Su, Scott P. Myrand, Jin Hyoung Kang, Richard K. Rosenberg, Ji Lin, Sameera R. Wijayawardana, Mary Pinder-Schenck, Scott M. Hynes, Giorgio V. Scagliotti, Aimee Bence Lin, Emily Nash Smyth, David J. Smith, Keunchil Park, Sang We Kim, Thomas E. Boyd, Silvia Novello

المصدر: Investigational New Drugs. 34:625-635

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Combination therapy, Antineoplastic Agents, Pemetrexed, Pharmacology, 03 medical and health sciences, 0302 clinical medicine, Stable Disease, Pharmacokinetics, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Pharmacology (medical), CHEK1, Lung cancer, Protein Kinase Inhibitors, Aged, business.industry, Phenylurea Compounds, Common Terminology Criteria for Adverse Events, Middle Aged, medicine.disease, Treatment Outcome, 030104 developmental biology, Pyrazines, 030220 oncology & carcinogenesis, Checkpoint Kinase 1, Immunohistochemistry, Female, Tumor Suppressor Protein p53, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2928286c5402b6e0ba484dd6439a115Test
https://doi.org/10.1007/s10637-016-0368Test-1

تنقيح النتائج